Autologous Mitochondrial Transplant for Cerebral Ischemia

Status Recruiting

Clinical Trial Summary

The investigators propose to infuse healthy autologous mitochondria into cerebral vessels supplying brain tissue experiencing ischemia in patients who undergo standard-of- care endovascular reperfusion therapy.

Clinical Trial Description

Stroke is one of the leading causes of morbidity and mortality worldwide. More than 80% of strokes are the result of ischemia caused by blockage of one or more cerebral arteries. Lack of blood supply starves brain cells of necessary glucose and oxygen, and disturbs cellular homeostasis, eventually resulting in neuronal death. Mitochondria are tiny organelles present in nearly all types of human cells and are vital to our survival. Much like a battery, they generate most of our adenosine triphosphate (ATP), the energy currency of the cell. Mitochondria are also involved in other tasks, such as signaling between cells and cell death. All these functions can be impaired during ischemia because of the damage caused to mitochondria. Based on many preclinical studies in animals, damage caused by ischemia can be reversed after infusing healthy mitochondria into injured tissues. An ongoing clinical trial in human hearts at Boston Children's Hospital has also demonstrated that transplanting autologous mitochondria via infusion or direct injection is well-tolerated and safe. The investigators at the University of Washington are recruiting subjects for a first-in-human-brain trial to confirm the safety of autologous mitochondrial transplant during brain ischemia. The transplantation will be performed within the same procedure as the clinically indicated reperfusion treatment. During standard-of-care endovascular treatment for cerebral ischemia, the investigators will obtain a very small biopsy from the muscle tissue adjacent to our surgical access site. Muscle tissue will be processed at bedside to extract the autologous mitochondria as performed in prior human cardiac trial and validated in animal studies. The endovascular treatment proceeds without disruption as clinically indicated, and the mitochondria are infused into the brain artery via micro-catheter during reperfusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04998357
Study type	Interventional
Source	University of Washington
Contact	Study Coordinator
Phone	206-897-5802
Email	sanslab@uw.edu
Status	Recruiting
Phase	N/A
Start date	April 29, 2021
Completion date	October 29, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT04167527` - Endovascular Therapy for Low NIHSS Ischemic Strokes	Phase 2/Phase 3
Recruiting	`NCT04583163` - Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
Completed	`NCT01436812` - Effect of Positive End Expiratory Pressure (PEEP) on Cerebral Oxymetry During Laparoscopy	N/A
Terminated	`NCT00141011` - Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke	Phase 3
Recruiting	`NCT05053932` - Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
Completed	`NCT04437862` - A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke	N/A
Completed	`NCT00598819` - A Prospective Study of a New Device for Monitoring Cerebral Oxygenation on Healthy Volunteers	Phase 1
Completed	`NCT00207961` - The Threshold Value of Regional Cerebral Oxygenation in Detecting Cerebral Ischemia	N/A
Not yet recruiting	`NCT04696523` - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage	Phase 2
Completed	`NCT02351518` - Cerebral Autoregulation and Vasospasm in Patients With TBI
Completed	`NCT01546636` - The Effect of Ventilation on Cerebral Oxygenation in the Sitting Position	N/A
Completed	`NCT04047563` - Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke	Phase 3
Completed	`NCT05087836` - Correlation of Cerebral Oxygen Saturation Measured From 2 Sensor Sites: Forehead vs. Temporal
Completed	`NCT02448069` - Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke	Phase 2
Completed	`NCT02147275` - Monitoring Hypertensive Patients's Cerebral Oxygen Saturation	N/A
Completed	`NCT01875055` - Reversing Cerebral Oxygen Desaturations Greater That 10% of Baseline Values Using NIRS in the ICU	N/A
Completed	`NCT02389647` - Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury
Completed	`NCT02643030` - Hypercapnia During Shoulder Arthroscopy	N/A
Completed	`NCT01436799` - Desflurane Versus Propofol in the Sitting Position	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.